Non-bacterial infections in allogeneic non-myeloablative stem cell transplant recipients.
Data on non-bacterial infections during allogeneic non-myeloablative hematopoietic stem cell transplantation (HSCT) are widely different. We evaluated data on 48 consecutive patients who received a conditioning regimen with fludarabine and cyclophosphamide (73%) or fludarabine and total body irradiation (27%) and then underwent allogeneic non-myeloablative HSCT. Cytomegalovirus (CMV) infection was common and occurred in 48% of patients; 3 patients developed CMV disease, and all survived. CMV reactivation was found to be common with both conditioning regimens in our patient population. Invasive aspergillosis occurred in 4 patients (8%) and 3 died. Other serious non-bacterial infections were uncommon. Review of the available literature on non-myeloablative HSCT suggests that the frequency and type of opportunistic infections vary considerably.
Narreddy
S
S
Division of Infectious Diseases, Detroit Medical Center, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, USA.
Mellon-Reppen
S
S
Abidi
M H
MH
Klein
J L
JL
Peres
E
E
Heilbrun
L K
LK
Smith
D
D
Alangaden
G
G
Chandrasekar
P H
PH
D000047:Academies and Institutes; D000970:Antineoplastic Agents / Q000008:administration & dosage; D001228:Aspergillosis / Q000453:epidemiology* / Q000209:etiology*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003586:Cytomegalovirus Infections / Q000453:epidemiology* / Q000209:etiology*; D004359:Drug Therapy, Combination; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008297:Male; D008824:Michigan / Q000453:epidemiology; D008875:Middle Aged; D019653:Myeloablative Agonists / Q000008:administration & dosage; D009369:Neoplasms / Q000628:therapy; D009894:Opportunistic Infections / Q000453:epidemiology* / Q000209:etiology*; D012189:Retrospective Studies; D012196:Review Literature as Topic; D019172:Transplantation Conditioning / Q000009:adverse effects*; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives; D014916:Whole-Body Irradiation
D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D019653:Myeloablative Agonists; D003520:Cyclophosphamide; D014740:Vidarabine; C024352:fludarabine